Press Release

Ref. No.: WOCK/SEC/SE/2026-27/046 2nd November, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA Dear Sir/Madam, Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) - Press Release Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com Kindly take the same on record please. Thanking you, For Wockhardt Limited Rashmi Mamtura Company Secretary Encls: as above Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720 www.wockhardt.com Mumbai, Nov 2nd, 2026 Wockhardt Reports PAT of Rs. 73 Cr for Q2 FY 27 Driving Positive Momentum FINANCIAL HIGHLIGHTS Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 2nd Quarter Results for Financial Year 2026-27, today. Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720 www.wockhardt.com Q2 FY27 Performance: Revenue growth of 24% compared to previous year, revenue of Rs.969 Cr in Q2 FY27 compared to Rs.782 Cr in the previous year. EBITDA of Rs.165 Cr compared to Rs.160 Cr in the previous year and EBITDA of Rs 201 Cr Excluding pre Zaynich Launch Expenses. H1 FY27 Performance: Revenue growth of 25% compared to previous year, revenue of Rs.1898 Cr in H1 FY27 compared to Rs.1520 Cr in the previous year. EBITDA growth of 35% in EBITDA in H1 FY27 compared to previous year, EBITDA of Rs.353 Cr compared to Rs.261 Cr in the previous year and EBITDA of Rs 398 Cr Excluding pre Zaynich Launch Expenses. Financial Performance: Q2 FY27 Q2 FY26 Q1 FY27 H1 FY27 H1 FY26 Particulars Apr - Sep Apr - Sep Jul - Sep 2026 Jul - Sep 2025 Apr - Jun 2026 2026 2025 Total Revenue 9 69 782 929 1,898 1,520 EBITDA before R&D 1 94 194 221 4 15 3 22 EBITDA % to Sales 20.0% 24.8% 23.8% 21.9% 21.2% R&D 29 3 4 34 63 61 R&D % to Sales 3.0% 4.4% 3.6% 3.3% 4.0% EBITDA 1 65 160 188 3 53 2 61 EBITDA Margins % 17.0% 20.5% 20.2% 18.6% 17.2% EBITDA (Excluding pre Zaynich Launch exps.) 2 01 160 197 3 98 2 61 EBITDA Margins % 20.8% 20.5% 21.2% 21.0% 17.2% Exceptional Items ( 97) PBT 73 9 1 116 1 89 ( 18) PBT (Excluding pre Zaynich launch exps.) 1 09 9 1 125 2 34 ( 18) Profit After Tax 73 8 2 107 1 80 ( 26) PAT Margins % 7.5% 10.5% 11.5% 9.5% -1.7% Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720 www.wockhardt.com Biosimilar Highlights: 300 261 252 H1 FY26 H1 FY27 Q2-26 Q2-27 ▪ The overall Biotech operations for the quarter stood at Rs.252 crore recording a growth of 68% vs Q2 FY26. On half yearly basis the Biotech operations recorded 87% growth while delivering Rs 487 crore. This robust achievement is fuelled by our Emerging Market biotech segment growing at ~110% in H1 FY27 with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key markets like Brazil, Thailand, Egypt, Algeria and LATAM. Our India Biotech operations continues to grow at double digit pace and is poised for decent growth in the future. ▪ The Company’s strength lies in robust and end to end well integrated Biotech infrastructure. ▪ We remain committed to meeting global diabetes healthcare needs and advancing our leadership in diabetes care. Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720 www.wockhardt.com Business Highlights: Region-wise Revenue Highlights: Q1 FY27 Regions Currency Q2 FY27 Q2 FY26 H1 FY27 H1 FY26 India & Emerging Market 156 India Branded Business INR Cr 146 1 36 303 265 46 India-Others INR Cr 45 36 9 2 85 263 Emerging Market INR Cr 310 2 04 574 374 EU & UK 27 UK GBP Mn 28 27 5 5 54 11 Others Euro Mn 10 10 2 1 17 929 Total revenue INR Cr 969 782 1,898 1 ,520 ▪ India Branded Business stood at Rs.146 crore in Q2 FY27 with a growth of 8% compared to the previous year. On half yearly basis the business stood at Rs.303 crore in H1 FY27 with a growth of 14% compared to the previous year. The India Business growth was aided by substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK) and the introduction of Regenerative Derma segment. ▪ UK region stood at GBP 28 Mn in Q2 FY27 with a growth of 4% compared to the previous year. On half yearly basis the business stood at GBP 55 Mn in H1 FY27 with a growth of 2% compared to the previous year. ▪ Emerging Markets region stood at Rs.310 crore in Q2 FY27 with a growth of 52% compared to the previous year. On half yearly basis the business stood at Rs.574 crore in H1 FY27 with a growth of 54% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth. ▪ Irish region stood at EUR 6 Mn in Q2 FY27. On half yearly basis the business stood at EUR 11 Mn in H1 FY27 with a growth of 13% compared to the previous year. Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720 www.wockhardt.com New Products Launch: ▪ 24 Filings, 18 Approvals and 11 launches in our International Business. ▪ Biosimilars 2 Filing and 4 Approvals and NCE - 1 Filing & 2 Approvals. ▪ Approval received for EMROK O and EMROK injection in Uganda. Novel Antibiotics: Key Updates: Five Novel Antibiotics from Wockhardt completed Phase 3 Clinical Trials successfully: Emrok®, Emrok O®, Miqnaf®, Zaynich® and Foviscu®. ❖ ZAYNICH®: ➢ Approved in US: On May 29, US FDA approved Zaynich for the treatment of cUTI including Pyelonephritis making it 1st ever India-discovery and developed drug gaining approval from US FDA. ➢ EMA review process: EMA review process is progressing. In response to the Marketing Authorization Application (MAA), the EMA has communicated that the submitted dossier is adequate for review for the proposed indications, including complicated urinary tract infection (cUTI), complicated intra- abdominal infections (cIAI), hospital-acquired pneumonia/ventilator- associated pneumonia (HAP/VAP) and bloodstream infections (BSI). ➢ CDSCO approval: Approval received for Manufacturing and marketing received on August 25, 2026. Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720 www.wockhardt.com ❖ EMROK®/ EMROK O®: ➢ Growth rate of 40% vs previous year Q2 FY26 & 37% vs previous year H1 FY26. ➢ Continues to address critical unmet need in the treatment of difficult-to- manage Gram-positive infections, including bone and joint infections, diabetic foot infections, and pneumonia. ➢ On track to become the leading brands in the anti-MRSA therapy segment. ❖ MIQNAF® NAFITHROMYCIN: approved and launched in India. ➢ Removal of “supply condition” by DCGI – Now facililitates marketing access to wider patient population. ➢ Field force deployed to align with the supply condition removal for ease of drug access. ➢ Increasing acceptance within the clinical community owing to comprehensive coverage of pathogens and shorter course of therapy. Filling for additional indication of Upper Respiratory Tract Infections will be done in Q3/Q4 FY27. ❖ FOVISCU® (WCK 4282): ➢ India Phase 2 & Phase 3 Clinical Trial completed successfully. NDA Filling completed recently. ➢ Underwent comb [Showing first 8,000 characters — download PDF for full document]